metronidazole has been researched along with Diabetic Feet in 5 studies
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.
metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Against 182 anaerobe and 241 aerobe strains obtained from diabetic foot infections, doripenem was the most active carbapenem against Pseudomonas aeruginosa (MIC(90), 2 microg/ml), more active than imipenem against Proteus mirabilis, and ertapenem was more active against Escherichia coli and Klebsiella spp." | 7.74 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. ( Citron, DM; Fernandez, HT; Goldstein, EJ; Merriam, CV; Tyrrell, KL; Warren, YA, 2008) |
| "Against 182 anaerobe and 241 aerobe strains obtained from diabetic foot infections, doripenem was the most active carbapenem against Pseudomonas aeruginosa (MIC(90), 2 microg/ml), more active than imipenem against Proteus mirabilis, and ertapenem was more active against Escherichia coli and Klebsiella spp." | 3.74 | In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. ( Citron, DM; Fernandez, HT; Goldstein, EJ; Merriam, CV; Tyrrell, KL; Warren, YA, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goldstein, EJ | 1 |
| Citron, DM | 1 |
| Merriam, CV | 1 |
| Warren, YA | 1 |
| Tyrrell, KL | 1 |
| Fernandez, HT | 1 |
| Vivas, LLY | 1 |
| Gold, WL | 1 |
| Mandell, DM | 1 |
| Wu, PE | 1 |
| Lee, SU | 1 |
| Jung, IE | 1 |
| Kim, HJ | 1 |
| Kim, JS | 1 |
| Clay, PG | 1 |
| Graham, MR | 1 |
| Lindsey, CC | 1 |
| Lamp, KC | 1 |
| Freeman, C | 1 |
| Glaros, A | 1 |
| Al-Ebous, AD | 1 |
| Hiasat, B | 1 |
| Sarayrah, M | 1 |
| Al-Jahmi, M | 1 |
| Al-Zuriqat, AN | 1 |
2 trials available for metronidazole and Diabetic Feet
| Article | Year |
|---|---|
Clinical efficacy, tolerability, and cost savings associated with the use of open-label metronidazole plus ceftriaxone once daily compared with ticarcillin/clavulanate every 6 hours as empiric treatment for diabetic lower-extremity infections in older mal
Topics: Aged; Anti-Bacterial Agents; Bacterial Infections; Ceftriaxone; Clavulanic Acids; Cost Savings; Diab | 2004 |
Management of diabetic foot in a Jordanian hospital.
Topics: Amikacin; Amputation, Surgical; Anti-Bacterial Agents; Ceftazidime; Chemotherapy, Adjuvant; Debridem | 2005 |
3 other studies available for metronidazole and Diabetic Feet
| Article | Year |
|---|---|
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
Topics: Anti-Bacterial Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; Carbapenems; Di | 2008 |
An 82-year-old man with ataxia and dysarthria.
Topics: Aged, 80 and over; Anti-Infective Agents; Ataxia; Brain; Cerebellar Nuclei; Diabetes Mellitus, Type | 2016 |
Metronidazole-induced combined peripheral and central vestibulopathy.
Topics: Aged; Anti-Infective Agents; Diabetes Mellitus; Diabetic Foot; Humans; Hypertension; Male; Metronida | 2016 |